 |
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved an expanded label for COPAXONE® (glatiramer acetate injection) to include the treatment of patients with clinical isolated syndrome (CIS) suggestive of multiple sclerosis (MS).
To read more about this news story, as reported by the MS Trust UK, click here.
Source: MS Trust UK
|
